The funding chasm and how to cross it

By Bernard Ross, Founder and CEO at Sky Medical Technology Ltd.

The UK is a renowned international home for tech start‑ups; particularly medtech and biotech.

This should not be a surprise, given the various initiatives that have consistently aimed to provide funding support to match the enviable academic output from our great universities and research hospitals.

When we started Sky Medical Technology, ten years ago, we found our initial seed‑ stage funding relatively easy to access. The mixture of Angel support and grant funding available made this part of the journey relatively straight forward. Nowadays, an even more developed Angel‑ ecosystem and a mature crowd funding sector means pre‑seed funding is arguably more accessible than ever.

Indeed, once a company is producing significant revenues and ARR, then series B funding is also relatively easy to access. A key metric for these growth‑focussed venture capitalists appears to be £1m+ of annual recurring revenue. At this point, you could well hold a beauty parade of abundant VCs to find the right partner.

However, there is a potential gap between these early seed funding and late Series A/ early Series B stages where it can be more difficult to raise the capital and receive the support growth‑driven innovation requires.

This is, perhaps dramatically, named by some as ‘the chasm of death.’ This is where a company needs significant cash, we can be talking millions, to go from initial proof of concept through to revenue growth. This is where the UK Government’s Enterprise Investment Scheme (EIS) provides incentives to private investors to support growth‑ focussed early‑state companies. Our journey at Sky Medical would not have been the same without EIS – I am sure we would have got to where we are without EIS funding, but it may have taken considerably longer. Having EIS funding to help us to build on early commercial and clinical interest was invaluable. Therefore, my ‘top tip number one,’ for anybody seeking to start and scale a medtech company in the UK, is to ensure you check out the Enterprise Investment Scheme and Seed Enterprise Investment Scheme and, if you meet the criteria, gain Advance Assurance from Her Majesty’s Revenue and Customs. This simple exercise will ensure that your options are widened.

The UK is home to great funding and support, so it was no surprise to me that a PWC report in 2017, commissioned by the European Union, reviewed more than forty tax incentivised schemes from across the globe and, when ranked by good practice, found the UK to have four of the top six schemes.

Once you have an outline of funding journey plan, then my ‘top tip number two’ is choose your funding partners carefully. Decide whether you want passive (also known as ‘dumb’) capital that gives you the cash and then leaves you to crack on and report back, or whether you want smart capital from investors which provide active support to assist you to grow your business with more than just money. We were fortunate to work with Deepbridge Capital and other partners that not only believed in what we were doing, but importantly understood the commercial route we needed to take and the sector in which we were operating. This smart capital allowed us access to support and advice when required. Developing a business is hugely rewarding, but it can be a lonely existence at times, so to have a supportive VC backer is a big positive. Finally, my ‘top tip number three’ is to understand the funding journey. Whatever you think you need at the outset will change, and probably multiply, as time passes. Matters will probably take longer than you expect, which is why funding for growth companies is rightly described as patient capital. Understanding the types of funding available and when they might become appropriate is important.

Every stage of funding represents a significant milestone for any company. At pre‑seed, it could represent a single individual agreeing with your concept. At seed‑stage, it could be business angels or an early‑stage VC putting faith in you and your team to develop your product. At the Series A level, it probably means that you have developed initial commercial or clinical traction. At Series B, you are likely to be receiving the backing that your business has global opportunities to exploit. Then of course, could be an IPO or M&A activity as the company grows. When it comes to Series B and beyond, you will likely have access to international funding opportunities, so you can choose where in the world works best for you ‑ in our case, this has worked hand‑in‑glove with our global distribution partners.

Having travelled the world with Sky Medical, I can honestly say that if I was starting over again, I would absolutely start the company in the UK and would be delighted to work with our funding partners again. There may be a funding gap for those companies at the early stage of commercialisation, but I would suggest that in the UK this is not the ‘chasm’ it is sometimes portrayed to be.

Being an entrepreneur and starting a tech‑based business is the best job in the world, but it is important to choose funding partners carefully.

Sky Medical Technology Limited received £3.25m of funding via the Deepbridge Technology Growth EIS. In 2017, a partial exit provided investors with returns of up to 4.8x.

The Deepbridge Technology Growth EIS has to date provided over £100m of funding to highly innovative early‑stage companies.

IF IT AIN’T BROKE, DO FIX IT.

The mindset of innovators and entrepreneurs is to constantly challenge accepted norms and identify solutions for problems many of us would not even know existed. This is how great technology and life sciences innovations are founded.

Deepbridge’s EIS funds invest in growth-focused innovative technology and life sciences companies, allowing investors to reap the potential rewards of supporting great innovations from an early-stage, whilst bene ting from the generous tax reliefs available via the UK Government’s Enterprise Investment Scheme.

www.deepbridgecapital.com

EIS MONTHLY DEPLOYMENTS | ONLINE APPLICATIONS | GROWTH FOCUSED

Capital at risk. EIS and SEIS investments are illiquid and unquoted stocks and therefore should be considered as high risk. Tax reliefs are dependent on individual circumstances, cannot be guaranteed and may be subject to change. Seek independent nancial advice. Issued by Deepbridge Capital LLP, a limited liability partnership registered in England & Wales, registration No. OC356449. Registered of ce: Deepbridge House, Honeycomb East, Chester Business Park, Chester CH4 9QN. Deepbridge Capital LLP is authorised and regulated by the Financial Conduct Authority (FRN: 563366).

Deepbridge Capital LLP Deepbridge House Honeycomb East Chester Business Park Chester CH4 9QN Tel: +44 (0) 1244 746000 Email: info@deepbridge.com www.deepbridge.com

Deepbridge Capital LLP is registered in England & Wales, registration number OC356449. Registered Office: Deepbridge House, Honeycomb East, Chester Business Park, Chester CH4 9QN. Deepbridge Capital LLP is authorised and regulated by the Financial Conduct Authority (FRN: 563366).

WINNER

EISA AWARDS

2021 & 2020

SPIRIT OF EIS 2021

WINNER

TEAM OF THE YEAR 2021

FINALISTS: INDUSTRY GAME CHANGER MOST IMPACTFUL INVESTMENT MOST VALUABLE PLAYER GROWTH INVESTOR OF THE YEAR TEAM OF THE YEAR